...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products
【24h】

Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products

机译：嵌合抗原受体T细胞疗法治疗侵袭性B细胞非霍奇金淋巴瘤：疗效，毒性和比较嵌合抗原受体产物

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

ABSTRACT Introduction: Traditionally, outcomes for patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma have been poor. There has been a clear need for effective therapeutic options that could produce durable remissions with a reasonable safety profile. The approval of chimeric antigen receptor (CAR) T-cell therapies has been revolutionary in the field because CART-cells meet this need for a substantial number of patients. With multiple approved CAR T-cell products and more expected soon, it can be difficult to distinguish between the various products and decide which to use. Effective CAR T-cell therapeutic choice is enhanced by an understanding of the biology of CAR T-cell, as well as the mechanisms associated with both efficacy and toxicity. Areas Covered: Biology of CAR T-cells, as well as a discussion of their efficacy and toxicity. Mechanisms of resistance, current unanswered questions in the field, issues associated with choosing a CAR T-cell product, and future directions for the advancement of CAR T-cell therapy. Expert Opinion: Due to differences in study populations and manufacturing times, it is too early to know if there is a 'best' choice for CAR T-cell therapy. Decisions must be individualized taking into account patient factors and expected toxicity.
机译：摘要介绍：传统上，复发/难治性侵略性B细胞非霍奇金淋巴瘤的患者的结果差。有明确的需要有效的治疗选择，可以产生合理的安全概况的持久解除。嵌合抗原受体（轿厢）T细胞疗法的批准在该领域已经革命性，因为购物车细胞满足大量患者的需求。通过多种批准的汽车T细胞产品，很快预期，可能难以区分各种产品并决定使用该产品。通过了解汽车T细胞的生物学来增强有效的汽车T细胞治疗选择，以及与疗效和毒性相关的机制。涵盖的区域：汽车T细胞的生物学，以及讨论它们的疗效和毒性。抵抗机制，现场的当前未解答的问题，与选择汽车T细胞产品相关的问题，以及汽车T细胞疗法进程的未来方向。专家意见：由于研究人口和制造时间的差异，现在知道是否有“最佳”的汽车T细胞疗法选择。决定必须考虑到患者因素和预期的毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号